PED5 inhibitors are the preferred treatment for ED

erectile dysfunction (ED) is one of the most common sexual dysfunctions in men, and data from the National Health and Health Survey (NHWS) show that the overall prevalence of ED in China is 40.5%. On the occasion of the 21st China Men's Health Day, Professor Jiang Hui, President of the Chinese Society of Sexuality and Director of the Men's Department and Human Sperm Bank at Peking University's Third Hospital, said at the "Wan Ai Kokou Collapse Listing Conference" held in Beijing on October 25th: "There are many factors that lead to ED, some or even many factors at the same time, and heavy stress and long-term unhealthy living habits are often the triggers of ED disease." For ED to early detection, early treatment, face up to the emotional and physiological needs of patients, and actively choose formal treatment channels and treatment methods. In
1980s, researchers at Pfizer's European Research Center were looking for new drugs to treat a variety of cardiovascular diseases, including angina, said Professor Jiang Hui. It was at that time that the phosphateinhibitor, sidnaphets, was developed. Over the past 20 years, the treatment from surgical treatment to drug therapy ED treatment has been continuously developed, but at present oral type 5 phosphate dylsterase (PDE5) inhibitors are still the preferred method of ED treatment.
Professor Zhou Huiliang, a male professor at the First Hospital affiliated with Fujian Medical University, said that theacid sidna is not a PDE5 inhibitor, and its pharmacological effect is mainly by inhibiting PDE5 on the smooth muscles of blood vessels, thus playing a role in dilation of blood vessels. As the world's first PDE5 inhibitor treatment ED clinical application is widely used, safe tolerance is good, quick to start, drug absorption and peak concentration is stable, significantly improve the sexual life satisfaction of both partners, clinically on-demand, long-term or regular use of the efficacy is accurate
Professor Zhou Huiliang said that the study showed that because ED may be a local manifestation of various systemic diseases, and cardiovascular diseases, diabetes and other chronic diseases are closely related, the regular use of PDE5 inhibitors can not only improve the endothor function of blood vessels, effective treatment of ED, the prevention and treatment of systemic diseases in patients also have some help, so the regular use of PDE5 is currently more used treatment methods. Wan Ai delicious chip is currently on the Chinese market with thin-film clothing bio-equivalent of the only original PDE5 inhibitor, can be easily taken, put a few seconds on the tongue can disintegrate, the fastest 12 minutes of effect, more conducive to increasing patient treatment compliance, more benefits and doctors to provide ED first-line treatment drug new options.
Professor Jiang Hui said that ED is a chronic disease that affects the physical and psychological conditions of patients and their sexual partners at the same time, with the rapid development of social economy, the pace of life accelerated, the number of ED patients is on the rise and constantly developing towards youth. Oral PDE5 inhibitors are easy to use, safe and effective, can help more patients to raise disease awareness, receive scientific and standardized treatment, while the development and market of new drugs also promote the continuous development of clinical research in men's science.